{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:33Z","timestamp":1793508753298,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jpurol.2022.11.020","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T22:23:53Z","timestamp":1669674233000},"page":"175.e1-175.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2870-9225","authenticated-orcid":false,"given":"Takeya","family":"Kitta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Darekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-6603","authenticated-orcid":false,"given":"Philip","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2022.11.020_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-5347(06)00305-3","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society","volume":"176","author":"Neveus","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/nau.24211","article-title":"EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment","volume":"39","author":"Stein","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2022.11.020_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40272-017-0249-x","article-title":"Pharmacotherapy for pediatric neurogenic bladder","volume":"19","author":"Kroll","year":"2017","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jpurol.2022.11.020_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/nau.22751","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society","volume":"35","author":"Austin","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2022.11.020_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00042307-200211000-00005","article-title":"Conservative management in neurogenic bladder dysfunction","volume":"12","author":"Aslan","year":"2002","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0090-4295(02)01793-4","article-title":"Special considerations of the overactive bladder in children","volume":"60","author":"Bauer","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2022.11.020_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ucl.2017.04.012","article-title":"Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity","volume":"44","author":"Kaviani","year":"2017","journal-title":"Urol Clin"},{"key":"10.1016\/j.jpurol.2022.11.020_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2377-14-74","article-title":"Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity","volume":"14","author":"Tang","year":"2014","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib9","first-page":"217","article-title":"The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts","volume":"28","author":"Madersbacher","year":"1990","journal-title":"Paraplegia"},{"key":"10.1016\/j.jpurol.2022.11.020_bib10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/nau.24024","article-title":"Are EAU\/ESPU pediatric urology guideline recommendations on neurogenic bladder well received by the patients? Results of a survey on awareness in spina bifida patients and caregivers","volume":"38","author":"Dogan","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2022.11.020_bib11","first-page":"182","article-title":"Overactive bladder: pharmacologic treatments in the neurogenic population","volume":"10","author":"Kennelly","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/nau.22248","article-title":"International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children","volume":"31","author":"Rawashdeh","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2022.11.020_bib13","series-title":"Full prescribing information","year":"2021"},{"key":"10.1016\/j.jpurol.2022.11.020_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169694","article-title":"Early fesoterodine fumarate administration prevents neurogenic detrusor overactivity in a spinal cord transected rat model","volume":"12","author":"Biardeau","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jpurol.2022.11.020_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/iju.14319","article-title":"Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and\/or low compliance bladder","volume":"27","author":"Kaga","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5347(17)54449-3","article-title":"Prognostic value of urodynamic testing in myelodysplastic patients","volume":"126","author":"McGuire","year":"1981","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(17)38389-1","article-title":"An objective score to predict upper tract deterioration in myelodysplasia","volume":"145","author":"Galloway","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1601-0825.2003.03967.x","article-title":"Drug effects on salivary glands: dry mouth","volume":"9","author":"Scully","year":"2003","journal-title":"Oral Dis"},{"key":"10.1016\/j.jpurol.2022.11.020_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/15569527.2015.1072547","article-title":"The short-term and long-term adverse ocular effects of fesoterodine fumarate","volume":"35","author":"Erginturk Acar","year":"2016","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib20","series-title":"Full prescribing information","year":"2014"},{"key":"10.1016\/j.jpurol.2022.11.020_bib21","first-page":"743","article-title":"An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude","volume":"9","author":"Sekeroglu","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11934-011-0198-9","article-title":"Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients","volume":"12","author":"Pagoria","year":"2011","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.jpurol.2022.11.020_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2012.05.2543","article-title":"Evaluation of cognitive function in healthy older subjects treated with fesoterodine","volume":"124","author":"Kay","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jpurol.2022.11.020_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5213\/inj.2040082.041","article-title":"Cognitive function and urologic medications for lower urinary tract symptoms","volume":"24","author":"Kim","year":"2020","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.jpurol.2022.11.020_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jpurol.2012.02.008","article-title":"Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder","volume":"8","author":"Malhotra","year":"2012","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.jpurol.2022.11.020_bib27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5489\/cuaj.6247","article-title":"A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: the FOXY study","volume":"14","author":"Ramsay","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.jpurol.2022.11.020_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000499757","article-title":"Can oral fesoterodine Be an alternative for intravesical oxybutynin instillations in children with neuropathic bladder dysfunction?","volume":"103","author":"van den Heijkant","year":"2019","journal-title":"Urol Int"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513122005356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513122005356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:52:34Z","timestamp":1761486754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513122005356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1477513122005356"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2022.11.020","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2022.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}